Abiopharma

X4 Pharmaceuticals to Participate in Guggenheim’s Second Annual Healthcare Innovation Conference

Rhythm Pharmaceuticals annonce le remboursement public de lIMCIVREE® (setmélanotide) au Canada dans cinq provinces et dans le cadre du Programme fédéral des services de santé non assurés

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results

Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program

Curaleaf Reports Third Quarter 2025 Results: Solid Growth and Robust Cash Generation

Cytokinetics Reports Third Quarter 2025 Financial Results and Provides Business Update

Acumen Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 12, 2025

Virgin River Season 7: Everything We Know So Far (November 2025 Update)

What Is 2K Resolution: Understanding Display Standards in 2026